Results 31 to 40 of about 4,765 (162)
Metabolites, 2021 Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines
Anne Scheunemann +7 more
doaj +1 more source
PM&R, EarlyView.Abstract Background and Objective Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine.
Matthew Chen +7 more
wiley +1 more source
Phytotherapy Research, EarlyView.ABSTRACT The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis
Rafael Leite Pacheco +5 more
wiley +1 more source
Health Technology Assessment, 2015 Background: The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ9-tetrahydrocannabinol (Δ9-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid ...
Susan Ball +11 more
doaj +1 more source
Frontiers in Psychiatry, 2020 Alzheimer’s Dementia (AD) is a devastating neurodegenerative disease that affects approximately 17% of people aged 75–84. Neuropsychiatric symptoms (NPS) such as delusions, agitation, anxiety, and hallucinations are present in up to 95% of patients in ...
Michaela Defrancesco, Alex Hofer
doaj +1 more source
Addiction, EarlyView.Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Immune checkpoint inhibitors (ICIs) are now standard of care for most advanced solid tumors. While effective, they are associated with immune‐related adverse events (irAEs), including rare autonomic complications. We present a patient with metastatic lung adenocarcinoma receiving nivolumab and ipilimumab who developed reflex syncope with ...
Ashley Bouzon +3 more
wiley +1 more source
Clinical Pharmacology: Advances and Applications, 2017 D Alexander Oh, Neha Parikh, Varun Khurana, Christina Cognata Smith, Santosh VetticadenINSYS Therapeutics, Inc., Chandler, AZ, USA Abstract: Dronabinol is a pharmaceutical tetrahydrocannabinol originally developed as an oral capsule.
Oh DA +4 more
doaj